Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06369259 · ClinicalTrials.gov registry record · Phase 2
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
A Phase 2 study of Advanced Colorectal Cancer, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT06369259 is a Phase 2 study of Advanced Colorectal Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 33 participants, below the 179-participant average among 8 other Advanced Colorectal Cancer trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06369259, a Phase 2 study of Advanced Colorectal Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if avutometinib in combination with defactinib and cetuximab can help to control unresectable, anti-EGFR-refractory, advanced colorectal cancer.
Conditions Studied
Interventions
- DRUG Avutometinib
- DRUG Defactinib
- DRUG Cetuximab
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2025-02-24 |
| Est. Completion | 2029-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06369259
The ClinicalTrials.gov registry entry for NCT06369259 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 8 other Advanced Colorectal Cancer trials with a reported enrollment target (82% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Avutometinib is the first listed.
NCT06369259 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06369259 about?
NCT06369259 is a clinical study titled "Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer". To learn if avutometinib in combination with defactinib and cetuximab can help to control unresectable, anti-EGFR-refractory, advanced colorectal cancer.
What is the current status of trial NCT06369259?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2025-02-24. Estimated completion is 2029-02-01.
What conditions does trial NCT06369259 study?
This clinical trial studies the following conditions: Advanced Colorectal Cancer.
What interventions are being tested in trial NCT06369259?
The interventions under investigation include: Avutometinib (DRUG), Defactinib (DRUG), Cetuximab (DRUG).
Who is sponsoring clinical trial NCT06369259?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06369259 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
RECRUITING · Phase 2
-
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
COMPLETED · Phase 2
-
Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer
COMPLETED · Phase 2
-
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
RECRUITING · Phase 1
-
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.